Targets › F10
55 programs from 47 companies in 81 trials: 38 Phase 4, 26 Phase 3, 9 Phase 2, 8 Phase 1; Cardiovascular, Oncology, Hematology; next expected readout Nov 2026.
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting. Factor Xa activates pro-inflammatory signaling pathways in a protease-activated receptor (PAR)-dependent manner. (UniProt, P00742)
Open in Phaseline: the race on F10, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Emicizumab Coagulation factor IX and X other | F9, F10 | Phase 4 | Severe Hemophilia A; Von Willebrand Disease, Type 3; Factor VIII Deficiency, Congenital; Hemophilia A Patient … | Nov 2026 |
| Hospital Sirio-Libanes | Edoxaban Coagulation factor X inhibitor | F10 | Phase 4 | Atrium; Fibrillation | Dec 2026 |
| Ottawa Hospital Research Institute | Rivaroxaban Coagulation factor X inhibitor | F10 | Phase 4 | Atrial Fibrillation; Venous Thromboembolism; SVT | Dec 2026 |
| China National Center for Cardiovascular Diseases | Rivaroxaban Coagulation factor X inhibitor | F10 | Phase 4 | Coronary Artery Disease; Atrial Fibrillation | Dec 2026 |
| Assistance Publique - Hôpitaux de Paris | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Stroke; Intrahepatic Non Cirrhotic Portal Hypertension | Dec 2026 |
| Herlev and Gentofte Hospital | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Deep Vein Thrombosis; Atrial Fibrillation | Mar 2027 |
| Herlev and Gentofte Hospital | Edoxaban Coagulation factor X inhibitor | F10 | Phase 4 | Deep Vein Thrombosis; Atrial Fibrillation | Mar 2027 |
| Herlev and Gentofte Hospital | Rivaroxaban Coagulation factor X inhibitor | F10 | Phase 4 | Deep Vein Thrombosis; Atrial Fibrillation | Mar 2027 |
| Asian Institute Of Medical Sciences | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Cirrhosis | Apr 2027 |
| Children's Hospital of Fudan University | Rivaroxaban Coagulation factor X inhibitor | F10 | Phase 4 | Kawasaki Disease | Jun 2027 |
| Population Health Research Institute | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Stroke; Bleeding Post Cardiac Surgery | Jun 2027 |
| Population Health Research Institute | Edoxaban Coagulation factor X inhibitor | F10 | Phase 4 | Stroke; Bleeding Post Cardiac Surgery | Jun 2027 |
| Population Health Research Institute | Rivaroxaban Coagulation factor X inhibitor | F10 | Phase 4 | Stroke; Bleeding Post Cardiac Surgery | Jun 2027 |
| Imperial College London | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Venous Thromboembolism | Jun 2027 |
| Korea University Anam Hospital | Rivaroxaban Coagulation factor X inhibitor | F10 | Phase 4 | Atrial Fibrillation | Jun 2027 |
| Kiranya Arnold | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Venous Thromboembolism | Sep 2027 |
| The University of The West Indies | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Coronary Artery Disease | Oct 2027 |
| Chinese Academy of Medical Sciences, Fuwai Hospital | Rivaroxaban Coagulation factor X inhibitor | F10 | Phase 4 | Mitral Regurgitation | Oct 2027 |
| University of Birmingham | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Atrial Fibrillation; Thromboprophylaxis | Dec 2027 |
| Ottawa Hospital Research Institute | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Atrial Fibrillation; Venous Thromboembolism | Dec 2027 |
| Karolinska Institutet | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Left Ventricular Thrombus | Apr 2028 |
| Clinical Urology and Epidemiology Working Group | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Venous Thromboembolism | Sep 2028 |
| Yonsei University | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation; Stroke | Oct 2028 |
| Vastra Gotaland Region | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Takotsubo Syndrome | Dec 2028 |
| Samsung Medical Center | Edoxaban Coagulation factor X inhibitor | F10 | Phase 4 | Atrial Fibrillation (AF) | Jun 2031 |
| VA Office of Research and Development | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Atrial Fibrillation | Oct 2032 |
| Mansoura University | Apixaban Coagulation factor X inhibitor | F10 | Phase 4 | Cirrhosis | – |
| Children's Hospital Los Angeles | Feiba Activated prothrombin complex concentrate (aPCC) - contains vitamin K-dependent clotting f | F2, F7, F10 | Phase 4 | Hemophilia A With Inhibitor | – |
| Yale University | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Intracerebral Hemorrhage | Apr 2027 |
| University Hospital, Brest | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Polycythemia Vera | Jul 2027 |
| Region Stockholm | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Chronic Kidney Diseases | Dec 2027 |
| Walton Centre NHS Foundation Trust | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Traumatic Intracranial Haemorrhage | Dec 2027 |
| University of Arizona | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Left Ventricular Thrombus | Jul 2028 |
| Takeda | TAK-330 Factor Xa inhibitor reversal agent (recombinant human Factor Xa) | F10 | Phase 3 | Coagulation Disorder | Aug 2028 |
| Queen Mary University of London | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Thrombosis | Aug 2028 |
| Texas Cardiac Arrhythmia Research Foundation | apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Atrial Fibrillation (AF) | Dec 2028 |
| University Hospital, Lille | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Intracerebral Hemorrhage | Jan 2029 |
| VarmX | Reltodecacog alfa (VMX-C001) Factor X (prothrombin complex) analog | F10 | Phase 3 | Blood Loss, Surgical | Jan 2029 |
| Columbia University | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | LVAD (Left Ventricular Assist Device) Thrombosis | Aug 2029 |
| Sunnybrook Health Sciences Centre | Edoxaban Coagulation factor X inhibitor | F10 | Phase 3 | Stroke, Ischemic | Dec 2031 |
| University of Vermont | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Cancer | Aug 2035 |
| Icahn School of Medicine at Mount Sinai | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Atrial Fibrillation | – |
| National Institute of Cardiovascular Diseases, Pakistan | Apixaban Coagulation factor X inhibitor | F10 | Phase 3 | Acute Myocardial Infarction of Anterior Wall | – |
| Icahn School of Medicine at Mount Sinai | Edoxaban Coagulation factor X inhibitor | F10 | Phase 3 | Atrial Fibrillation | – |
| Icahn School of Medicine at Mount Sinai | Oral Anticoagulant (OAC) - Vitamin K Antagonist (VKA) or Direct Oral Anticoagula Vitamin K antagonist or factor Xa/IIa inhibitor anticoagulation | F2, F7, F9, F10 | Phase 3 | Atrial Fibrillation | – |
| University of Vermont Medical Center | Apixaban Coagulation factor X inhibitor | F10 | Phase 2 | Glioblastoma | Dec 2026 |
| Centre Hospitalier Universitaire Dijon | apixaban Coagulation factor X inhibitor | F10 | Phase 2 | Prolonged Anticoagulation | Aug 2028 |
| Northwell Health | FEIBA Factor VIII inhibitor bypass activity - prothrombin complex concentrate containing factors | F2, F7, F9, F10 | Phase 2 | Cardiac Disease | Nov 2028 |
| Centre Hospitalier Universitaire Vaudois | Apixaban Coagulation factor X inhibitor | F10 | Phase 2 | Liver Cirrhosis | – |
| Centre Hospitalier Universitaire Vaudois | Edoxaban Coagulation factor X inhibitor | F10 | Phase 2 | Liver Cirrhosis | – |
| Insel Gruppe AG, University Hospital Bern | Apixaban Coagulation factor X inhibitor | F10 | Phase 1 | Liver Cirrhosis | Dec 2026 |
| Bayer | BAY3389934 Factor IIa (thrombin) and Factor Xa inhibitor | F2, F10 | Phase 1 | Sepsis; Drug-drug Interaction | Dec 2026 |
| Hyewon Chung | Edoxaban Coagulation factor X inhibitor | F10 | Phase 1 | Healthy | – |
| Shaanxi Micot Pharmaceutical Technology | MT1011 Factor IIa and Factor Xa inhibitor reversal agent | F2, F10 | Phase 1 | Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation | – |
| Thomas Jefferson University | Rivaroxaban Coagulation factor X inhibitor | F10 | Phase 1 | Postpartum | – |
Atrial Fibrillation (13) Venous Thromboembolism (6) Stroke (5) Deep Vein Thrombosis (3) Liver Cirrhosis (3) Bleeding Post Cardiac Surgery (3) Intracerebral Hemorrhage (2) Atrial Fibrillation (AF) (2) Left Ventricular Thrombus (2) Coronary Artery Disease (2) Postpartum (2) Severe Hemophilia A (2)
small molecule (52), mixed (2)
Herlev and Gentofte Hospital (3) Population Health Research Institute (3) Icahn School of Medicine at Mount Sinai (3) Ottawa Hospital Research Institute (2) Centre Hospitalier Universitaire Vaudois (2) University Hospital, Lille (1) Texas Cardiac Arrhythmia Research Foundation (1) Karolinska Institutet (1) Imperial College London (1) China National Center for Cardiovascular Diseases (1) Thomas Jefferson University (1) Queen Mary University of London (1) Roche (1) Clinical Urology and Epidemiology Working Group (1) The University of The West Indies (1) Kiranya Arnold (1) Centre Hospitalier Universitaire Dijon (1) Takeda (1) Insel Gruppe AG, University Hospital Bern (1) Yale University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.